Updates in Heart Failure 2024

Chairs: Gianluigi Savarese, Frieder Braunschweig

Organized by: Karolinska University Hospital
in collaboration with Translational medicine agency (TMA)

December 16th-17th 2024

DECEMBER 16th 2024 (DAY 1)

12.00-13.00

Lunch

13.00-13.05 

  • 13.00-13.05 | Greetings and introduction to the congress
    Savarese G (SE), Braunschweig F (SE)
Session 1: Implementation of GDMT: time to act (joint session with the Heart Failure Association of the European Society of Cardiology)

Chairpersons: Chioncel O (RO),  Metra M (IT), Bayes-Genis A (ES)

13.05-14.20

  • 13.05-13.15 | The secret recipe for starting the 4 pillars
    Mebazaa A (FR)
  • 13.15-13.25 | How are we doing with ARNi and SGLT2i?
    Stolfo D (SE)
  • 13.25-13.35 | Breaking down barriers: the point of view of the nephrologist on worsening renal function during GDMT
    Burton J (UK)
  • 13.35-13.45 | Breaking down barriers: hyperkalemia – are we reaching a consensus for its management?
    Savarese G (SE)
  • 13.45-13.55 | Why do we talk about implementation?
    Lindberg F (SE)
  • 13.55-14.05 | What strategies to implement use of GDMT? 
    Savarese G (SE)
  • 14.05-14.50 | Round Table: Ask the experts
    All

14.35-14-50

Coffee Break
Session 2: Post-MI heart failure

Chairpersons: Petrie M (UK), Cannata A (UK), Lund LH (SE)

14.50-16.00

  • 14.50-15.00 | The sizes of the problem
    Ferrannini G (SE)
  • 15.00-15.10 | The DAPA-MI: drawing conclusions
    James S (SE)
  • 15.10-15.20 | The EMPACT-MI: the last piece of the puzzle?
    Butler J (US)
  • 15.20-15.30 | How do we reconcile data on the treatment of post-MI HF
    Solomon S (US)
  • 15.30-16.00 | Round Table: Ask the experts
    All

16.00-16.15

Coffee Break
Session 3: Iron deficiency in HF: have we gained enough evidence? 

Chairpersons: Braunschweig F (SE), Savarese G (SE), Chioncel O (RO)

16.15-17.15

  • 16.15-16.25 | Iron deficiency in HF: a summary of evidence until 2023
    Rosano G (UK)
  • 16.25-16.35 | FAIR-HF2: the last piece of evidence
    Anker S (DE)
  • 16.35-16.45 | How do we reconcile evidence and future perspectives
    Cleland J (UK)
  • 16.45-17.15 | Round Table: Ask the experts
    All
  • 17.15-17.40 | Lecture 1: New advances in the field of cardioncology (15 min presentation + 10 min Q&A) 
    Chair: Månsson-Broberg A (SE), Anker M (DE)
  • 17.40-17.55 | Lecture 2: Hypertension and HFpEF (15 min presentation + 10 min Q&A) 
    Chair: Savarese G (SE), Manolis A (GR)
  • 17.55-18.00 | Closure of the day
    Savarese G (SE), Braunschweig F (SE)

December 17th 2024 (day 2)

DECEMBER 17th 2024 (DAY 2)
  • 08.25-08.30 | Greetings
    Savarese G (SE), Braunschweig F (SE)
  • 08.30-08.55 | Lecture 3: Management of HFpEF: the world beyond SGLT2i (15 min presentation + 10 min Q&A) 
    Chair: Lund LH (SE), Solomon S (SE)
Session 4: GLP1Ra – a new pillar in HF pharmacotherapy?

08.55-10.15

Chairpersons: Rosano G (UK), Anker SD (DE), Bayes-Genis A (ES)

  • 08.55-09.05 | Obesity: a therapeutic target in patients with HF?
    Bozkurt B (US)
  • 09.05-09.15 | GLP1Ra in HF: the available evidence
    Petrie M (UK)
  • 08.15-09:25 | What is coming next?
    Butler J (US)
  • 09.25-09:55 | Round Table: Ask the experts
    All
  • 09.55-10.15 | Lecture 4: Increasing patient adherence in patients with HF (15 min presentation + 10 min Q&A) 
    Chair: Böhm M (DE), Rosano G (UK)
Coffee Break

10.15-10.30

Session 5: Heart Failure Devices

Chairpersons: Cleland J (UK), Stålberg M (SE), Bayes-Genis A (ES)

10.30-11.30

  • 10.30-10.40 | Primary prophylactic ICD in HF: towards precision medicine
    Braunschweig F (SE)
  • 10.40-10.50 | CRT: when is OMT and time to proceed with implantation?
    Linde C (SE)
  • 10.50-11.00 | Monitoring devices
    Melin M (SE)
  • 11.00-11.30 | Round Table: Ask the experts
    All
Session 6: Treating mitral and tricuspid regurgitation in HF

11.30-12.30

Chairpersons: Gustafsson F (DK), Bozkurt B (US), Solomon S (US)

  • 11.30-11.40 | Updates in the treatment of TR
    Metra M (IT)
  • 11.40-11.50 | Where do we stand for the treatment of fMR?
    Rück A (SE)
  • 11.50-12.00 | Treating aortic stenosis in HFrEF: when is it too late or too early?
    Adamo M (IT)
  • 12.00-12.10 | Lessons learnt from previous trials on TEER: how to design the next?
    Butler J (US)
  • 12.10-12.40 | Round Table: Ask the experts
    All

12.40-13.40

Lunch
  • 13.40-14.05 | Lecture 5: Atrial fibrillation in HF: drugs or interventions? (15 min presentation + 10 min Q&A) 
    Chair: Cleland J (UK), Braunschweig F
  • 14.05-14.30 | Lecture 6: Advanced heart failure: state-of-the art and future perspectives (15 min presentation + 10 min Q&A) 
    Chair: Melin M (SE), Gustafsson F

14.30-14.45

Coffee Break
Session 7: Non only heart failure… cardiomyopathies!

14.45-16.00

Chairpersons: Stolfo D (SE), Chioncel O (RO), Eldhagen P (SE)

  • 14.45-14.55 | Cardiac amyloidosis: current and future treatments
    Fontana M (UK)
  • 14.55-15.05 | Hypertrophic cardiomyopathy: current and future treatments
    Cannata A (UK)
  • 15.05-15.15 | Laminopathies: current treatment and future perspectives 
    Haugaa K (NO)
  • 15.15-16.00 | Round Table: Ask the experts
    All
Session 8: The best of HF publications in 2024

16.00-16.15

Chairpersons: Metra M (IT), Hage C (SE)

  • 16.00-16.10 | ESC Journals
    Böhm M (IT)
  • 16.10-16.20 | JACC Journals
    Bozkurt B (US)
  • 16.30-16.40 | Circ Journals
    Schiatterella G (DE)
  • 16.40-16.55 | Lecture 7: What to expect in 2025  (15 min presentation) 
    Chair: Savarese G (SE), Lund LH
  • 16.55-17.00 | Closure of the day
    Savarese G (SE), Braunschweig F (SE)
Scroll to Top